PDS Biotech Jumps as Soon-Shiong-Backed Financing Eases Funding Pressure

PDS Biotechnology Corporation (PDSB) is up 30.1% today. Here is some analysis on what might have caused this price movement. Analysis: The sharp move appears tied to PDS Biotech's announcement of up to $22.55 million in PIPE financing led by Nant Capital, alongside board involvement from Dr. Patrick Soon-Shiong and a plan to push PDS0301 toward late-stage development. For a small clinical-stage biotech that recently reported limited cash, investors likely viewed the financing as both a balance-sheet lifeline and a strategic endorsement. Details: PDS Biotech disclosed an initial financing expected to bring in about $11.55 million, with another $11 million tied to a milestone involving submission of a registrational Phase 3 protocol for PDS0301 to the FDA. Nant will be able to designate two board members if it keeps a large enough ownership stake, and one of those designees is expected to be Dr. Patrick Soon-Shiong. The company said the proceeds are intended to repay outstanding indebtedness and support working capital, research, development, and continued clinical programs. PDS Biotech's June 30, 2026 quarterly update showed cash and cash equivalents of about $5.6 million, so the new capital may have reduced near-term financing concerns and improved confidence in advancing PDS0301. Sources: SEC, PDS Biotech, Yahoo Finance Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes. Quiver Alerts Receive PDSB Data Alerts Get market-moving data, filings, and signals for PDSB in real time. Sign Up $PDSB Hedge Fund Activity We have seen 26 institutional investors add shares of $PDSB stock to their portfolio, and 18 decrease their positions in their most recent quarter. Here are some of the largest recent moves: FOCUS PARTNERS WEALTH added 642,177 shares (+inf%) to their portfolio in Q2 2026, for an estimated $565,822 QUANTINNO CAPITAL MANAGEMENT LP added 642,177 shares (+inf%) to their portfolio in Q2 2026, for an estimated $565,822 MILITIA CAPITAL MANAGEMENT LLC added 331,800 shares (+inf%) to their portfolio in Q2 2026, for an estimated $292,348 MORGAN STANLEY added 310,000 shares (+7904.1%) to their portfolio in Q2 2026, for an estimated $273,141 JANE STREET GROUP, LLC added 279,664 shares (+inf%) to their portfolio in Q2 2026, for an estimated $246,411 SQUAREPOINT OPS LLC removed 192,556 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $116,496 ARMISTICE CAPITAL, LLC removed 173,605 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $152,963 To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint. This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.